肺癌风险模型(PLCOM2012与LLPv2)在社区肺癌筛查项目中的性能分析
该研究在曼彻斯特贫困地区55-74岁曾吸烟者中开展社区肺癌筛查,比较PLCOM2012、LLPv2与NLST标准的筛查资格判定性能。PLCOM2012≥1.51%与LLPv2≥2.5%均筛选出56%的受检者,但NLST标准与LLPv2≥5%筛选人数更少。PLCOM2012可能低估英国贫困人群的肺癌风险,需进一步校准研究。
要点
- PLCOM2012≥1.51%与LLPv2≥2.5%筛查阳性率均为56%,NLST为47%,LLPv2≥5%为33%。
- NLST标准漏诊18%的肺癌病例,LLPv2≥5%漏诊26%,LLPv2≥2.5%漏诊7%。
- 冠状动脉钙化可预测肺癌(adjOR 2.50,95%CI 1.11-5.64;p=0.028)。
核心结论
- PLCOM2012模型可能低估英国贫困人群的肺癌风险,需进一步校准研究。
- 不同风险预测工具筛选资格存在差异,需前瞻性比较以优化筛查选择。
研究设计与样本
- 社区为基础的肺癌筛查项目,邀请曼彻斯特贫困地区55-74岁曾吸烟者参加肺健康检查。
- 高危者(PLCOM2012评分≥1.51%)接受两轮年度低剂量CT筛查,共纳入1429例筛查对象。
主要发现
- 两轮筛查共诊断62例肺癌,占平均PLCOM2012评分预测6年发病率的87%(62/71)。
- PLCOM2012≥1.51%筛选56%(n=1429),LLPv2≥2.5%亦筛选56%(n=1430),NLST筛选47%(n=1188),LLPv2≥5%筛选33%(n=826)。
- 肺癌病例中,LLPv2≥5%未入选26%(16/62),NLST未入选18%(11/62),LLPv2≥2.5%未入选7%(5/62)。
- 气流阻塞、呼吸道症状和心血管疾病与肺癌风险正相关;冠状动脉钙化预测肺癌的adjOR为2.50(95%CI 1.11-5.64;p=0.028)。
关键数值与推荐
- PLCOM2012评分≥1.51%作为筛查资格阈值。
- LLPv2评分≥2.5%和≥5%阈值用于分析比较。
- NLST eligibility criteria用于比较筛查资格。
临床怎么用
- 在贫困社区人群中采用PLCOM2012可能低估风险,需考虑模型校准。
- 选择筛查资格标准时应权衡检出率与漏诊比例,LLPv2≥5%漏诊较多。
局限性
- PLCOM2012模型在英国贫困人群中的校准不足,可能低估风险。
- 需前瞻性比较不同风险预测工具以优化筛查选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Low-dose CT (LDCT) screening of high-risk smokers reduces lung cancer (LC) specific mortality. Determining screening eligibility using individualised risk may improve screening effectiveness and reduce harm. Here, we compare the performance of two risk prediction models (PLCOM2012 and Liverpool Lung Project model (LLPv2)) and National Lung Screening Trial (NLST) eligibility criteria in a community-based screening programme. METHODS: Ever-smokers aged 55-74, from deprived areas of Manchester, were invited to a Lung Health Check (LHC). Individuals at higher risk (PLCOM2012 score ≥1.51%) were offered annual LDCT screening over two rounds. LLPv2 score was calculated but not used for screening selection; ≥2.5% and ≥5% thresholds were used for analysis. RESULTS: PLCOM2012 ≥1.51% selected 56% (n=1429) of LHC attendees for screening. LLPv2 ≥2.5% also selected 56% (n=1430) whereas NLST (47%, n=1188) and LLPv2 ≥5% (33%, n=826) selected fewer. Over two screening rounds 62 individuals were diagnosed with LC; representing 87% (n=62/71) of 6-year incidence predicted by mean PLCOM2012 score (5.0%). 26% (n=16/62) of individuals with LC were not eligible for screening using LLPv2 ≥5%, 18% (n=11/62) with NLST criteria and 7% (n=5/62) with LLPv2 ≥2.5%. NLST eligible Manchester attendees had 2.5 times the LC detection rate than NLST participants after two annual screens (≈4.3% (n=51/1188) vs 1.7% (n=438/26 309); p<0.0001). Adverse measures of health, including airflow obstruction, respiratory symptoms and cardiovascular disease, were positively correlated with LC risk. Coronary artery calcification was predictive of LC (adjOR 2.50, 95% CI 1.11 to 5.64; p=0.028). CONCLUSION: Prospective comparisons of risk prediction tools are required to optimise screening selection in different settings. The PLCOM2012 model may underestimate risk in deprived UK populations; further research focused on model calibration is required.
引用
- Lebrett MB, Balata H, Evison M, et al. Analysis of lung cancer risk model (PLCOM2012 and LLPv2) performance in a community-based lung cancer screening programme. Thorax. 2020. PMID: 32631933. doi:10.1136/thoraxjnl-2020-214626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。